19. Clinical benefit table: Hyalgan versus arthroscopy. Continuous outcome measures.

Study	TIme	Treatment	Outcome (scale)	N of Pts	Baseline Mean	End of Study Mean	Absolute Benefit	Relative Difference
Forster 2003	1 wk	T: Hyalgan	Pain (0‐10 cm VAS)	18	7.6	6.6	1.0 (W)	13.4% (W)
		C: Arthroscopy		15	7.5	5.4
Forster 2003	5‐13 wk	T: Hyalgan	Pain (0‐10 cm VAS)	18	7.6	6.0	‐0.1 (I)	‐1.5% (I)
		C: Arthroscopy		15	7.5	6.0
Forster 2003	14‐26 wk	T: Hyalgan	Pain (0‐10 cm VAS)	18	7.6	5.3	‐1.1 (I)	‐14.1% (I)
		C: Arthroscopy		15	7.5	6.2
Forster 2003	45‐52 wk	T: Hyalgan	Pain (0‐10 cm VAS)	18	7.6	5.7	‐0.2 (I)	‐2.3% (I)
		C: Arthroscopy		15	7.5	5.7
Forster 2003	1 wk	T: Hyalgan	Knee Society Function Scale	18	64.4	66.5	‐5.6 (W)	‐13.3% (W)
		C: Arthroscopy		15	42.0	49.6
Forster 2003	5‐13 wk	T: Hyalgan	Knee Society Function Scale	18	64.4	67.5	6.3 (W)	14.9% (W)
		C: Arthroscopy		15	42.0	51.3
Forster 2003	14‐26 wk	T: Hyalgan	Knee Society Function Scale	18	64.4	73.5	1.0 (I)	2.4% (I)
		C: Arthroscopy		15	42.0	50.0
Forster 2003	45‐52 wk	T: Hyalgan	Knee Society Function Scale	18	64.4	75.0	1.5 (I)	3.5% (I)
		C: Arthroscopy		15	42.0	51.1
Forster 2003	1 wk	T: Hyalgan	Lequesne Index (0‐24)	18	11.4	11.1	2.4 (W)	18.1% (W)
		C: Arthroscopy		15	13.3	10.5
Forster 2003	5‐13 wk	T: Hyalgan	Lequesne Index (0‐24)	18	11.4	10.9	1.3 (W)	9.8% (W)
		C: Arthroscopy		15	13.3	11.5
Forster 2003	14‐26 wk	T: Hyalgan	Lequesne Index (0‐24)	18	11.4	8.7	‐1.2 (I)	‐8.6% (I)
		C: Arthroscopy		15	13.3	11.7
Forster 2003	45‐52 wk	T: Hyalgan	Lequesne Index (0‐24)	18	11.4	8.3	‐1.1 (I)	‐7.9% (I)
		C: Arthroscopy		15	13.3	11.2